KBC Group’s Stoke Therapeutics STOK Stock Holding History

KBC Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Hold	1,096	–	–	﹤0.01%	1794
2026 Q1	$36K	Buy	+1,096	New	+$35.9K	﹤0.01%	1752

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KBC Group's STOK Position: Q2 2026 in Review

KBC Group held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 1,096 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

KBC Group first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

KBC Group held 1,096 shares of Stoke Therapeutics worth $36K as of Q2 2026.
KBC Group left its Stoke Therapeutics share count unchanged in Q2 2026.
Stoke Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1794 holding.
KBC Group first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.